XOMA Royalty (XOMA) Restructuring Costs (2012 - 2026)
XOMA Royalty's (XOMA) quarterly Restructuring Costs came in at $11.0 million in Q1 2026, up 55.7% year-on-year from $7.1 million in Q1 2025, and up 0.65% quarter-over-quarter from $11.0 million in Q4 2025.
XOMA Royalty (XOMA) Restructuring Costs (2012 - 2026) Analysis & Trends
XOMA Royalty has disclosed Restructuring Costs across 11 years of filings, most recently posting $11.0 million for Q1 2026.
- Restructuring Costs for Q1 2026 came in at $11.0 million, up 55.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.4 million (up 8.35% YoY), and the FY2025 annual result was $29.4 million, down 6.57% from the prior year.
- Restructuring Costs came in at $11.0 million for Q1 2026 at XOMA Royalty, up from $11.0 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $18.1 million in Q4 2023 to a low of $4.1 million in Q1 2023.
- The 4-year median for Restructuring Costs is $7.0 million (2024), against an average of $8.5 million.
- Peak annual rise in Restructuring Costs reached 69.82% in 2024, while the deepest fall reached 64.24% in 2024.
- XOMA Royalty's Restructuring Costs stood at $18.1 million in 2023, then sank by 64.24% to $6.5 million in 2024, then jumped by 69.58% to $11.0 million in 2025, then rose by 0.65% to $11.0 million in 2026.
- The last three Restructuring Costs figures came in at $11.0 million (Q1 2026), $11.0 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.04 Mn |
| Dec 31, 2025 | 10.97 Mn |
| Sep 30, 2025 | 5.39 Mn |
| Jun 30, 2025 | 5.98 Mn |
| Mar 31, 2025 | 7.09 Mn |
| Dec 31, 2024 | 6.47 Mn |
| Sep 30, 2024 | 6.99 Mn |
| Jun 30, 2024 | 10.26 Mn |
| Mar 31, 2024 | 7.02 Mn |
| Dec 31, 2023 | 18.08 Mn |
| Mar 31, 2023 | 4.13 Mn |
| Dec 31, 2018 | 543,000.00 |
| Sep 30, 2018 | 909,000.00 |
| Jun 30, 2018 | 459,000.00 |
| Jun 30, 2017 | 1.46 Mn |
| Mar 31, 2017 | 2.02 Mn |
| Dec 31, 2016 | 4.55 Mn |
| Jun 30, 2016 | -21,000.00 |
| Mar 31, 2016 | 36,000.00 |
| Dec 31, 2015 | 1.14 Mn |